News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
723,717 Results
Type
Article (54170)
Company Profile (205)
Press Release (669326)
Multimedia
Podcasts (160)
Webinars (21)
Section
Business (200582)
Career Advice (3386)
Deals (35706)
Drug Delivery (144)
Drug Development (79632)
Employer Resources (192)
FDA (16394)
Job Trends (15465)
News (342013)
Policy (34349)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2892)
Accelerated approval (34)
Adcomms (35)
Allergies (143)
Alliances (48680)
ALS (177)
Alzheimer's disease (1736)
Antibody-drug conjugate (ADC) (330)
Approvals (16572)
Artificial intelligence (551)
Autoimmune disease (160)
Automation (37)
Bankruptcy (353)
Best Places to Work (12198)
BIOSECURE Act (23)
Biosimilars (199)
Biotechnology (132)
Bladder cancer (160)
Brain cancer (61)
Breast cancer (654)
Cancer (4953)
Cardiovascular disease (442)
Career advice (2874)
Career pathing (41)
CAR-T (295)
CDC (59)
Celiac Disease (1)
Cell therapy (791)
Cervical cancer (37)
Clinical research (67786)
Collaboration (1763)
Company closure (4)
Compensation (1039)
Complete response letters (72)
COVID-19 (2948)
CRISPR (97)
C-suite (872)
Cystic fibrosis (150)
Data (6254)
Decentralized trials (2)
Denatured (50)
Depression (149)
Diabetes (526)
Diagnostics (7002)
Digital health (45)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (263)
Drug pricing (223)
Drug shortages (35)
Duchenne muscular dystrophy (235)
Earnings (84486)
Editorial (64)
Employer branding (24)
Employer resources (166)
Events (113828)
Executive appointments (1023)
FDA (19527)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1530)
Gene editing (211)
Generative AI (48)
Gene therapy (644)
GLP-1 (1111)
Government (5184)
Grass and pollen (8)
Guidances (385)
Healthcare (20229)
HIV (60)
Huntington's disease (48)
IgA nephropathy (85)
Immunology and inflammation (286)
Immuno-oncology (61)
Indications (102)
Infectious disease (3232)
Inflammatory bowel disease (200)
Inflation Reduction Act (17)
Influenza (116)
Intellectual property (246)
Interviews (651)
IPO (17161)
IRA (59)
Job creations (3610)
Job search strategy (2322)
JPM (61)
Kidney cancer (17)
Labor market (89)
Layoffs (619)
Leadership (40)
Legal (8563)
Liver cancer (96)
Longevity (14)
Lung cancer (667)
Lymphoma (379)
Machine learning (43)
Management (64)
Manufacturing (825)
MASH (172)
Medical device (14252)
Medtech (14307)
Mergers & acquisitions (19647)
Metabolic disorders (1384)
Multiple sclerosis (162)
NASH (23)
Neurodegenerative disease (343)
Neuropsychiatric disorders (102)
Neuroscience (3039)
Neurotech (1)
NextGen: Class of 2026 (7135)
Non-profit (4931)
Now hiring (62)
Obesity (674)
Opinion (332)
Ovarian cancer (166)
Pain (209)
Pancreatic cancer (227)
Parkinson's disease (296)
Partnered (34)
Patents (498)
Patient recruitment (470)
Peanut (58)
People (60169)
Pharmaceutical (51)
Pharmacy benefit managers (32)
Phase 1 (20946)
Phase 2 (29897)
Phase 3 (22721)
Pipeline (5170)
Policy (334)
Postmarket research (2403)
Preclinical (8785)
Press Release (69)
Prostate cancer (245)
Psychedelics (57)
Radiopharmaceuticals (293)
Rare diseases (906)
Real estate (6074)
Recruiting (78)
Regulatory (25192)
Reports (52)
Research institute (2603)
Resumes & cover letters (557)
Rett syndrome (27)
RNA editing (18)
RSV (85)
Schizophrenia (159)
Series A (260)
Series B (198)
Service/supplier (18)
Sickle cell disease (103)
Special edition (27)
Spinal muscular atrophy (170)
Sponsored (46)
Startups (3990)
State (2)
Stomach cancer (19)
Supply chain (109)
Tariffs (99)
The Weekly (108)
Vaccines (1121)
Venture capital (96)
Weight loss (464)
Women's health (83)
Worklife (22)
Date
Last 7 days (615)
Last 30 days (2066)
Last 365 days (30822)
2026 (2900)
2025 (31299)
2024 (36185)
2023 (41183)
2022 (52536)
2021 (57175)
2020 (56109)
2019 (49595)
2018 (37710)
2017 (34194)
2016 (33478)
2015 (38841)
2014 (29865)
2013 (25467)
2012 (27176)
2011 (27885)
2010 (25371)
Location
Africa (968)
Alabama (88)
Alaska (7)
Arizona (281)
Arkansas (14)
Asia (42453)
Australia (7098)
California (11086)
Canada (3249)
China (1128)
Colorado (482)
Connecticut (487)
Delaware (331)
Europe (97431)
Florida (1672)
Georgia (371)
Hawaii (4)
Idaho (60)
Illinois (878)
India (65)
Indiana (527)
Iowa (22)
Japan (423)
Kansas (123)
Kentucky (38)
Louisiana (27)
Maine (79)
Maryland (1395)
Massachusetts (8127)
Michigan (337)
Minnesota (600)
Mississippi (6)
Missouri (133)
Montana (32)
Nebraska (27)
Nevada (124)
New Hampshire (84)
New Jersey (3046)
New Mexico (27)
New York (2995)
North Carolina (1525)
North Dakota (9)
Northern California (5395)
Ohio (338)
Oklahoma (22)
Oregon (43)
Pennsylvania (2191)
Puerto Rico (23)
Rhode Island (45)
South America (1319)
South Carolina (67)
South Dakota (1)
Southern California (4337)
Tennessee (175)
Texas (1728)
United States (40004)
Utah (325)
Vermont (1)
Virginia (268)
Washington D.C. (84)
Washington State (962)
West Virginia (4)
Wisconsin (114)
Wyoming (2)
723,717 Results for "valneva se".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
January 20, 2026
·
6 min read
Press Releases
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
January 1, 2026
·
7 min read
Press Releases
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®
February 3, 2026
·
8 min read
Press Releases
Valneva to Further Consolidate its Operations in France
November 27, 2025
·
3 min read
Press Releases
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
November 4, 2025
·
7 min read
Press Releases
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
November 26, 2025
·
9 min read
Press Releases
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
November 20, 2025
·
17 min read
Vaccines
FDA Pulls Valneva’s Chikungunya Shot From Market Citing ‘Serious Safety Concerns’
Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the regulator has reversed course.
August 25, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
September 30, 2025
·
6 min read
Press Releases
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
December 11, 2025
·
9 min read
1 of 72,372
Next
